Perceptive Supports Breakthrough Therapy Approvals for Oncology Treatments

Calyx Medical Imaging and other eClinical services provide critical support for clinical development programs to deliver much-needed therapies to market

Nottingham, UK – Jan. 19, 2021 — Calyx, the eClinical and regulatory solutions and services provider most relied on for solving complex data challenges in clinical research, today announced that its Medical Imaging and other eClinical solutions supported half of the oncology treatments approved by the FDA as Breakthrough Therapies in the past two years.

“We’re very proud that so many global researchers trust us to manage their important clinical trial data, which led to the availability of these much-needed cancer treatments,” said Gavin Nichols, CEO, Calyx. “Calyx has a long history of supporting successful new development programs, including over 250 new drug approvals, and we continually leverage that experience as we can help our clients solve their most complex challenges with innovative technology and scientific expertise.”

A Breakthrough Therapy designation allows the FDA to grant priority review to drug candidates if preliminary clinical trials indicate that the therapy may offer substantial treatment advantages over existing options for patients with serious or life-threatening diseases. Calyx’s Medical Imaging and other eClinical solutions were used in the development of half of the oncology treatments approved as Breakthrough Therapies since 2019.

Calyx’s eClinical solutions include Medical Imaging, Interactive Response Technology, Regulatory Information Management, Clinical Trial Management, and Electronic Data Capture.